G. Dennis Podlesak's most recent trade in Syndax Pharmaceuticals Inc was a trade of 50,000 Common Stock done . Disclosure was reported to the exchange on Feb. 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 50,000 | 191,763 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | G. Dennis Podlesak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 34,000 | 141,763 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 32,000 | 107,763 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 66,840 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Sale of securities on an exchange or to another person at price $ 24.20 per share. | 15 Sep 2022 | 66,840 | 75,763 (0%) | 0% | 24.2 | 1,617,381 | Common Stock |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 15 Sep 2022 | 66,840 | 142,603 (0%) | 0% | 6.3 | 422,429 | Common Stock |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Sale of securities on an exchange or to another person at price $ 23.43 per share. | 15 Sep 2022 | 6,556 | 75,763 (0%) | 0% | 23.4 | 153,625 | Common Stock |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 6,556 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.35 per share. | 15 Sep 2022 | 6,556 | 82,319 (0%) | 0% | 6.4 | 41,631 | Common Stock |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2022 | 5,419 | 0 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Sale of securities on an exchange or to another person at price $ 23.43 per share. | 15 Sep 2022 | 5,419 | 75,763 (0%) | 0% | 23.4 | 126,982 | Common Stock |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 15 Sep 2022 | 5,419 | 81,182 (0%) | 0% | 6.3 | 34,248 | Common Stock |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 32,000 | 75,763 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Other type of transaction at price $ 0.00 per share. | 05 Oct 2021 | 463 | 43,763 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Purchase of securities on an exchange or from another person at price $ 14.11 per share. | 22 Apr 2021 | 13,967 | 43,300 (0%) | 0% | 14.1 | 197,077 | Common Stock |
| Syndax Pharmaceuticals Inc | Dennis G. Podlesak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 29,333 | 29,333 (0%) | 0% | 0 | Common Stock |